Diagnostics News and Research RSS Feed - Diagnostics News and Research

New England Biolabs inks deal to supply critical reagents to TriLink BioTechnologies

New England Biolabs inks deal to supply critical reagents to TriLink BioTechnologies

New England Biolabs, Inc. (NEB®) has strengthened its position as a key supplier to the fast-growing RNA synthesis market by signing an agreement to supply critical reagents to TriLink BioTechnologies, Inc., a leading manufacturer of mRNA and long RNA for research, diagnostic and therapeutic applications. [More]
Kalorama Information: Global patient monitoring market worth $29.7 billion

Kalorama Information: Global patient monitoring market worth $29.7 billion

The global advanced patient monitoring market is currently worth about $29.7 billion, up 7% from last year, according to Kalorama Information. [More]
NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs

NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs

Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program. [More]
MyCartis announces launch of digital multiplex biomarker analysis platform

MyCartis announces launch of digital multiplex biomarker analysis platform

MyCartis today announced the launch of Evalution, a multiplex biomarker analysis platform for the life sciences research market. [More]
NanoString, BWH partner to translate genomic biomarker discoveries into clinical cancer diagnostics

NanoString, BWH partner to translate genomic biomarker discoveries into clinical cancer diagnostics

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. [More]
Study provides better glimpse at the biology of height

Study provides better glimpse at the biology of height

The largest genome-wide association study (GWAS) to date, involving more than 300 institutions and more than 250,000 subjects, roughly doubles the number of known gene regions influencing height to more than 400. [More]
Cepheid to acquire LABSCO's customer relationships for $21M

Cepheid to acquire LABSCO's customer relationships for $21M

Cepheid today announced that, effective today, it has entered into a purchase agreement to acquire the customer relationships from its former distribution partner, the Laboratory Supply Company (LABSCO). [More]
Allakos secures additional $10M investment to expand its development portfolio

Allakos secures additional $10M investment to expand its development portfolio

Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. [More]
Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease is the most common condition within a family of rare diseases known as the lysosomal storage diseases. The disease causes lipids to accumulate in cells, which is why it is referred to as a storage disorder. The accumulation occurs mainly in the spleen, liver, and bones, but may also occur in the lungs, heart, and central nervous system. [More]
Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients. [More]
Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. [More]
DNA Diagnostics Center launches new Paternity Test Kit

DNA Diagnostics Center launches new Paternity Test Kit

DNA Diagnostics Center, the world's largest DNA Paternity Testing Company, announces the launch of a new Paternity Test Kit to be sold in national retail stores, expanding the company's reach in the marketplace. [More]
Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration. [More]
Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics' Tumor BRACAnalysis CDx identifies 44% more candidates for PARP therapy

Myriad Genetics, Inc. today announced that its Tumor BRACAnalysis CDx- companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology annual meeting in Madrid, Spain. [More]
Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments. [More]
Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies. [More]
Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9. [More]

Abbott acquires CFR Pharmaceuticals; declares results of tender offer for CFR's ordinary shares

Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. [More]
Study: Simple blood test could identify people with hypercalcaemia

Study: Simple blood test could identify people with hypercalcaemia

High levels of calcium in blood, a condition known as hypercalcaemia, can be used by GPs as an early indication of certain types of cancer, according to a study by researchers from the universities of Bristol and Exeter. [More]